ClinicalTrials.gg
RecruitingNCT07235501Updated Oct 5, 2026

Kinetic Analysis of Immune Cells in Blood and Chronic Graft-Versus-Host Disease-Affected Tissues After Allogeneic Hematopoietic Cell Transplantation

An observational study in Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm and Malignant Solid Neoplasm, sponsored by City of Hope Medical Center. Recruiting at 1 site in United States. Open to participants aged 7 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by City of Hope Medical Center · Observational

How we know

Updated Oct 5, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
75
Ages
7 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Graft vs Host Disease by City of Hope Medical Center — 5 open to participants now, 6 under way, none of them phase 3. Graft vs Host Disease · City of Hope Medical Center.

Started
2026
with 1 other
Observational
2 of 11
1 open now
Registered
10th of 11
by date

Among the 11 studies in Graft vs Host Disease by City of Hope Medical Center, this one is one of 2 that started in 2026, is one of 2 observational ones, and was the 10th registered.

Graft vs Host Disease

804 studies on the registry are indexed under Graft vs Host Disease; 147 are open to participants now.

Browse Graft vs Host Disease studies →

Open to participants now

5 of the 11 studies in Graft vs Host Disease by City of Hope Medical Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 101 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 40 (40%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.

This study: 7 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Graft vs Host Disease by City of Hope Medical Center, or all of them as a file.
02

Study summary

This study evaluates the factors that contribute to chronic graft-versus-host disease, which is a complication that can occur after allogeneic hematopoietic cell transplantation.

Read the detailed description

PRIMARY OBJECTIVE:

I. Characterize immune cells and their subsets in peripheral blood of patients who develop and do not develop chronic graft-versus-host disease (cGVHD).

OUTLINE: This is an observational study. Patients are assigned to 1 of 2 cohorts.

COHORT 1: Patients undergo blood, saliva/buccal, and stool sample collection for up to 2 years on study. Patients also have their medical records reviewed on study.

COHORT 2: Patients undergo a one-time blood, saliva/buccal, and stool sample collection and have their medical records reviewed on study.

03

Conditions studied

  • Graft Versus Host Disease
  • Hematopoietic and Lymphatic System Neoplasm
  • Malignant Solid Neoplasm

Browse trials for

04

Who can participate

Ages eligible
7 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients who have received allogeneic hematopoietic cell transplant.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • * BOTH COHORTS:

    • Documented written of the participant and/or parent/guardian.

      • Assent from pediatric participants will be documented per institutional policies and practice.
    • Patients who have received hematopoietic cell transplant (HCT) regardless of donor type, condition regimen, or prophylaxis.
    • Age: ≥ 18 years or ≥ 7 years if 30 kg and above
    • Willingness to:

      • Provide blood sample(s), stool, saliva, and buccal mucosa,
      • If applicable: Permit medical record/ clinical laboratory result review

        • COHORT 1:
    • Patients who have received allogeneic hematopoietic cell transplant (HCT) regardless of donor type, condition regimen, or GVHD prophylaxis.

      • COHORT 2:
    • Patients diagnosed with cGVHD at any time-point after allogeneic HCT regardless of donor type, condition regimen, or GVHD prophylaxis.

Exclusion criteria

Exclusion Criteria:

  • * Women of : Pregnant/nursing

    • Individuals with impaired decision-making capacity
    • An employee who is under the direct/ indirect supervision of the PI/ a co-investigator/ the study manager
    • A direct study team member
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
75 participants (estimated)
Patient registry
No

Groups and cohorts

  • Observational Cohort 1

    Patients undergo blood, saliva/buccal, and stool sample collection for up to 2 years on study. Patients also have their medical records reviewed on study.

    Other: Non-Interventional Study

  • Observational Cohort 2

    Patients undergo a one-time blood, saliva/buccal, and stool sample collection and have their medical records reviewed on study.

    Other: Non-Interventional Study

Interventions

  • OtherNon-Interventional Study

    Non-interventional study

    Also known as: Non-Interventional Observational Study, Noninterventional (Observational) Study

06

What researchers measure

Primary outcomes

  1. T cell measurements

    Defined as percentage of naïve and memory T cells using high dimensional flow cytometry.

    Time frame: Up to 2 years - study completion

  2. B cell measurements

    Defined as percentage of naïve B, memory B, and plasma cells using high dimensional flow cytometry.

    Time frame: Up to 2 years - study completion

  3. Macrophage measurements

    Defined as percentage of M1, M2, and M0 using high dimensional flow cytometry.

    Time frame: Up to 2 years - study completion

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Jan 2030, 38 months later.

Of 45 non-industry observational studies under Graft vs Host Disease, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 154. This study's planned 38 months is below that.

Counting every sponsor, half of 46 studies reached it within 60 months; a quarter within 37 and three quarters within 154.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, on Oct 5, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2025
First posted
Nov 19, 2025
StartEst.
Nov 1, 2026was Oct 2026
Primary completionEst.
Jan 17, 2030
CompletionEst.
Jan 17, 2030
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 5, 2026
Sites
City of Hope Medical Center is now Recruiting
Oct 5, 2026
Start date
Oct 1, 2026→Nov 1, 2026
Oct 5, 2026
Sponsor
Collaborators added: National Heart, Lung, and Blood Institute (NHLBI)
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Not yet recruiting→Recruiting
    City of Hope Medical Center is now Recruiting
    Start date Oct 1, 2026→Nov 1, 2026
    Sponsor Collaborators added: National Heart, Lung, and Blood Institute (NHLBI)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07235501
Responsible party
Sponsor
First posted
Nov 19, 2025
Start date
Nov 1, 2026 (estimated)
Primary completion
Jan 17, 2030 (estimated)
Completion
Jan 17, 2030 (estimated)
Last update
Oct 5, 2026

Study contacts

Ryotaro Nakamura
principal investigator · City of Hope Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion